Recent study from Japan confirms the value of original GastroPanel® biomarkers diagnosis of autoimmune atrophic gastritis.

Biohit Oyj press release  9.5.2022 at 14.00 local time (EEST)

The publisher of the topmost medical journal Nature (1) reported recently a study that evaluated the accuracy of serological testing for the biomarkers (pepsinogens and gastrin) in diagnosis of autoimmune atrophic gastritis (AAG) (1). This cross-sectional study provides results that are similar as recently reported by Biohit partners in a population-based screening setting, where GastroPanel® showed unrivalled test characteristics in non-invasive screening of asymptomatic healthy people for AAG (2).  

AAG is characterized by atrophy of the corpus and fundus, and this condition is much more common in subjects affected by other autoimmune disorders, e.g., type 1 diabetes mellitus (DM1) or autoimmune thyroid disease (AITD)(1, 2,15). AAG is associated with significant co-morbidities, including vitamin-B12 deficiency (with pernicious anaemia), iron deficiency anaemia, osteoporosis, peripheral neuropathy, and gastric carcinoid tumours (1,14). Patients with AAG also have a 3- to 6-fold increased risk of GC (1, 2, 5, 15) (www.biohithealthcare.com/additional-information ).

This cross-sectional study aimed to examine whether pepsinogens, gastrin, and endoscopic findings can predict AAG in a clinical setting (1). 

In the Japanese study, the diagnostic accuracy of endoscopic findings and serology in distinguishing AAG was evaluated (1). Despite the fact that GastroPanel® test was not used in the Japanese study, the conclusions are identical to those reached in the recent screening study (2), where GastroPanel® proved to be an optimal screening test for AAG. This is important and confirms the universal applicability of the four biomarkers included in the GastroPanel® test. However, optimal performance is achieved when these biomarkers are used as a panel and the results are interpreted by special software application (GastroSoft®)(3-17).

Additional information:
CEO Päivi Siltala, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohit.fi

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

References

1.Kishikawa H, Nakamura K, Ojiro K, Katayama T, Arahata K, Takarabe S, Sasaki A, Miura S, Hayashi Y, Hoshi H, Kanai T, Nishida J. Relevance of pepsinogen, gastrin, and endoscopic atrophy in the diagnosis of  autoimmune gastritis. Sci Rep 2022;12(1):4202. doi: 10.1038/s41598-022-07947-1

2.Bakulina N, Tikhonov S, Malkov V, Vorobyev S, Belyakov I, Peshkova N, Belko E, Syrjänen K. Non-invasive screening of autoimmune atrophic gastritis (AAG) in asymptomatic subjects by serological biomarker (GastroPanel®) test. Anticancer Res 2022;42:1517-1526.

3.Koivurova O-P, Koskela R,  Blomster T, Ala-Rämi A, Lumme H,  Kettunen O,  Hukkanen J, Karttunen TJ, Mäkinen M, Ronkainen J, Syrjänen K. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients. Clinical validation of the new-generation GastroPanel® test. Anticancer Res 2021;41;5527-5537.

4.Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-147.

5.Syrjänen K, Eskelinen M, Peetsalu A, Sillakivi T, Sipponen P, Härkönen M, Paloheimo L, Mäki M, Tiusanen T, Suovaniemi O, DiMario F, Fan ZP.  GastroPanel® Biomarker Panel: The most comprehensive test  for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res 2019;39:1091-1104.

6.Syrjänen K. A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36: 5133-5144.

7.Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017;46:1-11. 

8.Kurilovich SA, Belkovets AV, Reshetnikov OV, Openko TG, Malyutina SK, Ragino YI, Scherbakova LV, Leja M, Paloheimo L, Syrjänen K, Voevoda MI. Stomach-specific biomarkers (GastroPanel®) can predict the development of gastric cancer in Caucasian population: A longitudinal nested case-control study in Siberia. Anticancer Res 2016;36:247-254.

9.Tiusanen T, Paloheimo L, Suovaniemi, O, Syrjänen K. Serological biomarker test (GastroPanel®) in diagnosis of functional gastric disorders, Helicobacter pylori and atrophic gastritis in a random sample of patients referred for testing due to dyspeptic symptoms. Anticancer Res 2021;41:811-819.

10.Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y. A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol 2017;112:704-715.

11.Cai Q,  Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y. and Gastrointestinal early cancer prevention & treatment alliance of China (GECA). Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multi-centre study. Gut 2019;68:1576-1587.

12.Chapelle N, Petryszyn P, Blin J, Le Berre-Scoul  C, Jirka I, Neunlist M, Moussata D, Lamarque D, Olivier R, Tougeron D, Mosnier J-F, Matysiak-Budnik T. A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. Helicobacter 2020;00:e12727. https://doi.org/10.1111/hel.12727

13.www.biohithealthcare.com /News/Reading material: State of the art GastroPanel and Acetium innovations for the unmet need  

14.https://www.gastropanel.com/decision-makers/screening-model

15.Koivurova O-P, Ukkola O, Koivikko M,  Ebeling T, Yliaska I, Koskela R,  Blomster T, Ala-Rämi A, Kettunen O, Karttunen TJ, Mäkinen M, Ronkainen J,  Syrjänen K. Screening of the patients with autoimmune thyroid disease (AITD) and type 1 diabetes mellitus (DM1) for atrophic gastritis (AG) by serological biomarker testing (GastroPanel®). EC Gastroenterol Digest Syst 2020;7:181-195.

16.Mäki M, Söderström D, Paloheimo L, Hendolin P, Suovaniemi O, Syrjänen K. Helicobacter pylori (Hp) IgG ELISA of the new-generation GastroPanel® is highly accurate in diagnosis of Hp-Infection in gastroscopy referral patients.  Anticancer Res 2020;40:6387-6398.

17. www.biohithealthcare.com/Critisism-about-current-care-recommendations